Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.63 |
| ▸ | PARP1 | P09874 | 4/20 | 0.63 |
| ▸ | CA12 | O43570 | 1/20 | 0.63 |
| ▸ | CA9 | Q16790 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | GPR3 | P46089 | 2/20 | 0.59 |
| ▸ | TNKS | O95271 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.59 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1342985 | 1.00 | KDM4E (0.63) | KDM4EPARP1CA12CA9ALDH1A1 | |
| SCHEMBL8873438 | 0.79 | PARP1 (0.74) | KDM4EPARP1CA12CA9ALDH1A1 | |
| Benzoylenurea SCHEMBL29407209 | 0.77 | KDM4E (1.00) | KDM4EPARP1CA12CA9ALDH1A1 | |
| Benzoylenurea SCHEMBL37945 | 0.77 | KDM4E (1.00) | KDM4EPARP1CA12CA9ALDH1A1 | |
| SCHEMBL2680080 | 0.77 | KMT2A (0.64) | KDM4EPARP1ALDH1A1KMT2AHSD17B10 | |
| Benzoylenurea SCHEMBL5072763 | 0.76 | KDM4E (0.95) | KDM4EPARP1CA12CA9ALDH1A1 | |
| Benzoylenurea SCHEMBL29722891 | 0.76 | KDM4E (0.95) | KDM4EPARP1CA12CA9ALDH1A1 | |
| Benzoylenurea SCHEMBL30526893 | 0.76 | KDM4E (0.95) | KDM4EPARP1CA12CA9ALDH1A1 | |
| 2-Mercaptobenzimidazole SCHEMBL29360590 | 0.75 | ALDH1A1 (1.00) | KDM4EALDH1A1KMT2AHSD17B10MEN1 | |
| 2-Mercaptobenzimidazole SCHEMBL705730 | 0.75 | ALDH1A1 (1.00) | KDM4EALDH1A1KMT2AHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120153320-A | Colored curable resin composition, color filter, display device, and solid-state imaging element | 住友化学株式会社 | 2025-06-13 | — | — | CN | disclosed |
| US-20240307394-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2024-09-19 | — | — | US | disclosed |
| US-20240228511-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | ELI LILLY AND COMPANY | 2024-07-11 | — | — | US | disclosed |
| EP-4216958-A2 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4150098-A1 | VIRAL VECTOR PRODUCTION | Oxford BioMedica (UK) Limited (GB) | 2023-03-22 | — | — | EP | disclosed |
| WO-2023039448-A1 | MRGPRX2 ANTAGONISTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-16 | — | — | WO | disclosed |
| CN-115667524-A | Viral vector production | 牛津生物医学（英国）有限公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2022261154-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | ELI LILLY AND COMPANY (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022067100-A2 | PLK1 POLO BOX DOMAIN INHIBITOR AND METHOD OF TREATING CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228511-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | KRAS, NRAS, TP53 | KDM4E 1034/4885PARP1 1019/4885CA12 3700/4885 |
| US-20240307394-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D AND RELATED PRODUCTS AND METHODS | MRGPRX1, MRGPRX4, MRGPRX2 | KDM4E 4555/4885PARP1 4563/4885CA12 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.